Effect of COVID-19 pandemic on glaucoma surgical practices in the UK
暂无分享,去创建一个
[1] Poemen P. Chan,et al. Treatment Outcomes Using the PAUL Glaucoma Implant to Control Intraocular Pressure in Eyes with Refractory Glaucoma. , 2020, Ophthalmology. Glaucoma.
[2] L. Quaranta,et al. Glaucoma Surgery During the COVID-19 Pandemic in Italy: How Novel Coronavirus has Changed the Surgical Management of Glaucoma Patients. , 2020, Journal of glaucoma.
[3] N. Kumaran,et al. Part 2 model eye simulation: aerosol generating procedures in intraocular surgery , 2020, Eye.
[4] T. Dada,et al. Preferred practice guidelines for glaucoma management during COVID-19 pandemic , 2020, Indian journal of ophthalmology.
[5] N. Kumaran,et al. Aerosol generating procedures in intraocular surgery , 2020, Eye.
[6] J. Liebmann. Ophthalmology and Glaucoma Practice in the COVID-19 Era , 2020, Journal of glaucoma.
[7] M. Schlenker,et al. Intermediate Outcomes of a Novel Standalone Ab Externo SIBS Microshunt with Mitomycin C. , 2020, American journal of ophthalmology.
[8] P. Bloom,et al. Micropulse transscleral cyclophotocoagulation: initial results using a reduced energy protocol in refractory glaucoma , 2020, Graefe's Archive for Clinical and Experimental Ophthalmology.
[9] W. Feuer,et al. Treatment Outcomes in the Primary Tube Versus Trabeculectomy Study after 1 Year of Follow-up. , 2018, Ophthalmology.
[10] N. Anand,et al. Deep sclerectomy for uveitic glaucoma: long-term outcomes , 2017, Eye.
[11] N. Anand,et al. Outcomes of combined phacoemulsification and deep sclerectomy: a 10-year UK single-centre study , 2015, Eye.
[12] A. Gupta,et al. Primary Phakic Deep Sclerectomy Augmented With Mitomycin C: Long-term Outcomes , 2011, Journal of glaucoma.